A Zinc Finger Protein-Based Prognostic Model in Lung Adenocarcinoma Identifies FGD3 as a Marker Associated with Lorlatinib Resistance
Cancers · 14.05.2026 · 18 (10) · 1591
DOI: 10.3390/cancers18101591 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 14.05.2026. Verfasst von Jiayue Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Harbin Medical University Cancer Hospital, No. 150, Haping Road, Harbin 150040, China. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Climbing Program of Harbin Medical University Cancer Hospital, Key Research and Development Program of Heilongjiang Province.
Abstract (Originalsprache)
Background
Lung adenocarcinoma (LUAD) is the most common type of lung cancer and a major cause of cancer death. Zinc finger proteins (ZNFs) have been implicated in LUAD progression, functioning either as oncogenes or tumor suppressors. Therefore, an in-depth investigation of ZNFs may contribute to the development of novel diagnostic and therapeutic strategies for LUAD.
Methods
Transcriptomic and clinical data were obtained from the TCGA and GEO databases. Prognosis-related ZNF genes were identified using univariate Cox, LASSO, and multivariate Cox regression analyses. An eight-gene ZNF-based prognostic signature was constructed and validated in two independent external cohorts (GSE50081 and GSE26939). A nomogram integrating independent prognostic factors was developed. Immune infiltration, somatic mutation profiles, and drug sensitivity were systematically analyzed. We further focused on FGD3, a key gene from the signature, examining its expression in LUAD cells and tissues, including lorlatinib-resistant models.
Results
The prognostic signature comprising TRIM6, TRIM29, CTCFL, FGD3, GATA4, CASZ1, TRAF2, and ZNF322 effectively stratified patients into distinct risk groups with significantly different overall survival (p < 0.05). The risk score, together with T and N stage, served as independent prognostic predictors (n = 500, p < 0.05). High-risk patients exhibited an immune-desert phenotype, increased tumor mutational burden, and distinct drug sensitivity patterns. Notably, FGD3 expression was downregulated in LUAD tissues (n = 14, p < 0.0001) and lorlatinib-resistant cells, and its restoration suppressed resistant cell proliferation and partially reversed drug resistance.
Conclusions
This study establishes a promising ZNF-based prognostic model for LUAD, providing a potential tool for risk stratification and individualized therapeutic decision-making. The identification of FGD3 as a potential mediator of drug resistance highlights its promise as a candidate biomarker and therapeutic target in LUAD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Harbin Medical University Cancer Hospital, No. 150, Haping Road, Harbin 150040, China.
- Biotherapy Center, Harbin Medical University Cancer Hospital, Harbin 150081, China.
- NHC Key Laboratory of Cell Transplantation, Harbin Medical University, Harbin 150081, China.
ORCID-Profile: Qingwei Meng
Förderung
- National Natural Science Foundation of China
- Climbing Program of Harbin Medical University Cancer Hospital
- Key Research and Development Program of Heilongjiang Province
Zitieren
APA
Sun, J., Yang, Y., Huang, X., Xue, D., Li, J., Huang, Y., & Meng, Q. (2026). A Zinc Finger Protein-Based Prognostic Model in Lung Adenocarcinoma Identifies FGD3 as a Marker Associated with Lorlatinib Resistance. Cancers, 18(10), 1591. https://doi.org/10.3390/cancers18101591
Vancouver
Sun J, Yang Y, Huang X, Xue D, Li J, Huang Y, et al. A Zinc Finger Protein-Based Prognostic Model in Lung Adenocarcinoma Identifies FGD3 as a Marker Associated with Lorlatinib Resistance. Cancers. 2026;18(10):1591. doi:10.3390/cancers18101591
BibTeX
@article{Sun2026,
author = {Sun, Jiayue and Yang, Yue and Huang, Xiaoyi and Xue, Dinglong and Li, Jiazhuang and Huang, Yaru and Meng, Qingwei},
title = {A Zinc Finger Protein-Based Prognostic Model in Lung Adenocarcinoma Identifies FGD3 as a Marker Associated with Lorlatinib Resistance},
journal = {Cancers},
year = {2026},
volume = {18},
number = {10},
pages = {1591},
doi = {10.3390/cancers18101591}
}
EUVIMED